Welcome to our dedicated page for Milestone Scientific news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scientific stock.
Milestone Scientific, Inc. (NASDAQ: MLSS) is a pioneering company in the field of medical and dental anesthesia. The company focuses on the development, manufacture, marketing, and sale of computer-controlled local anesthetic delivery (C-CLAD) systems designed to provide improved and painless local anesthetic delivery. These systems are marketed under various trademarks for different applications. For dentistry, the products are known as CompuDent™ and STA™ (Single Tooth Anesthesia) System. These innovative devices allow for painless injections during a wide range of dental procedures, from routine cleanings to complex surgeries involving implants, root canals, and crowns.
For medical applications, Milestone Scientific offers similar technology under the CompuMed™ trademark. Their products are used across various medical disciplines, including plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, and orthopedics. The company's advanced anesthetic delivery systems are sold both in the United States and in over 25 countries worldwide, highlighting their global reach and impact.
Besides their core product offerings, Milestone Scientific also provides The Wand™, a handpiece that allows for almost painless injections, enhancing patient comfort significantly.
The firm's operations are divided into two main segments: Dental and Medical. Geographically, all operations are concentrated in the United States, but their products are influential on a global scale.
Recent Achievements:
- Successful evaluations by prominent medical professionals, such as Dr. Matthew Stottle of Omaha Pain Physicians, achieving 100% success rates.
- Acceleration in reimbursement claims submission for the CompuFlo® Epidural System.
For more information or inquiries, Milestone Scientific can be contacted through Crescendo Communications, LLC via email at mlss@crescendo-ir.com or by phone at 212-671-1020.
Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Benzinga All Access event on December 16, 2021, at 10:40 A.M. Eastern Time. The presentation will recap key activities from 2021 and outline the company's sales pipeline and goals for 2022. The event will be broadcast live, and an archived recording will be accessible on Milestone's investor relations website. Milestone Scientific is known for its computerized drug delivery instruments, enhancing patient comfort and safety with innovative technologies.
Milestone Scientific (NYSE:MLSS) announced a significant step in expanding its CompuFlo Epidural instrument into the pain management market. Dr. Miguel de la Garza has started using the instrument in his practice, following approval by Surgery Partners, enhancing safety in procedures with reduced risk of complications. The overall addressable market for epidural anesthesia is around $5 billion, with pain management being twice the size of labor and delivery. CEO Arjan Haverhals emphasized the potential for capturing a significant market share with this innovative technology.
Milestone Scientific reported a 69% revenue increase to $2.1 million for Q3 2021, compared to $1.2 million in Q3 2020. This growth is driven by the reopening of dental offices and progress in their Medical segment, notably their CompuFlo Epidural instrument's deployment in Florida's Memorial Healthcare network. Despite the revenue growth, the operating loss expanded to $(2.0 million), up from $(1.5 million) in the prior year. The company has a robust financial position with about $14.5 million in cash. Milestone anticipates expanding its global presence with new distributors and aims for further growth in the medical business.
Milestone Scientific (NYSE: MLSS) announced a conference call scheduled for November 15, 2021, at 11:00 A.M. ET. The call will address the company’s third-quarter financial results for the period ending September 30, 2021, alongside updates on corporate progress and developments. Investors can access the call via telephone or a webcast. Additionally, an audio replay will be available until November 29, 2021. Milestone Scientific specializes in computerized drug delivery systems aimed at improving injection precision and patient comfort.
On October 18, 2021, Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021. The presentation is scheduled for 1:10 PM Eastern Time, with additional one-on-one meetings for qualified investors planned throughout the event. Interested parties can access the live webcast and archived recordings through the company's investor relations section. Milestone Scientific specializes in computerized drug delivery systems aimed at improving patient comfort during injections.
Milestone Scientific Inc. (NYSE:MLSS) has expanded its international presence by signing new distribution agreements in Canada, Slovenia, and the UAE for its CompuFlo Epidural Instrument. The partnerships aim to enhance women's health by providing safer pain relief during childbirth. Additionally, increased usage of the device at a leading German hospital showcases rising interest and demand.
Milestone Scientific Inc. (NYSE: MLSS) announced its participation in the Fall Harvest - Best Ideas from the Buy-Side conference, running from October 5-8, 2021. CEO Arjan Haverhals will present on October 6, 2021, at 9:30 AM ET, with the presentation available for live streaming and replay. This virtual conference features 36 top investment ideas recommended by qualified institutional investors. Milestone Scientific specializes in computerized drug delivery instruments aimed at enhancing patient comfort and safety during injections.
Milestone Scientific (NYSE:MLSS) has announced that Memorial Regional Hospital in Florida has begun utilizing its CompuFlo Epidural Instrument. This approval allows Milestone to supply both the CompuFlo and CathCheck Verification System disposables across the Memorial Healthcare System network. This milestone follows significant due diligence and expands Milestone’s sales pipeline. Clinical data supports that these instruments enhance safety and efficiency in epidural procedures, potentially reducing complications and costs for healthcare providers.
Milestone Scientific (MLSS) reported a significant revenue increase of 1,329% for Q2 2021, totaling $2.4 million, driven by a recovery in the dental sector. Gross profit rose to $1.4 million, with a reduced operating loss of $(2.9) million compared to $(3.2) million in Q2 2020. The company noted a healthy balance sheet with approximately $16 million in cash. CEO Arjan Haverhals expressed optimism about growth prospects, driven by new sales initiatives and expanding the sales force and international distribution.
Milestone Scientific (NYSE American: MLSS) announced a conference call on August 16, 2021, at 11:00 A.M. ET to discuss its second-quarter financial results and corporate developments. The call can be accessed via phone or webcast. An audio replay will be available until August 30, 2021. Milestone Scientific specializes in innovative drug delivery technologies, particularly for painless injections using its proprietary DPS Dynamic Pressure Sensing technology® for various medical applications. For further details, visit their website.
FAQ
What is the current stock price of Milestone Scientific (MLSS)?
What is the market cap of Milestone Scientific (MLSS)?
What does Milestone Scientific, Inc. do?
What are the main products offered by Milestone Scientific?
Where are Milestone Scientific’s products sold?
What recent achievements has Milestone Scientific accomplished?
What are the main segments of Milestone Scientific’s business?
How can Milestone Scientific be contacted?
What is The Wand™?
What is the STA™ System?
Which medical disciplines use Milestone Scientific’s systems?
What is CompuMed™?
